Abstract
Prostate cancer is the second leading cause of cancer related deaths in US men, largely because of metastasis, which is ultimately fatal. A better understanding of metastasis biology will lead to improved prognostication and therapeutics. We previously reported 11q13.1 gain was independently predictive of recurrence after radical prostatectomy. Multiple endocrine neoplasia I (MEN1) maps to this region of copy number gain in aggressive prostate tumors and was shown to be the only gene at this locus at increased expression in prostate cancer. Here, we demonstrate an oncogenic role for MEN1 in prostate cancer using a variety of independent assays.
| Original language | English |
|---|---|
| Journal | Prostate Cancer and Prostatic Diseases |
| Volume | 12 |
| Issue number | 2 |
| Pages (from-to) | 184-191 |
| Number of pages | 8 |
| ISSN | 1365-7852 |
| DOIs | |
| Publication status | Published - 2009 |
Funding
We thank Dr Nora Navone for generously donating the MDAPCA cells, Dr Francis Collins and Dr Lee Burns for kindly providing the MEN1 antibody, Bill Hyun and the UCSF Laboratory for cell analysis for assistance with FACS analysis, Applied Biosystems for supplying the reagents for the expression experiments, Christopher LaFargue for excellent technical assistance with the IHC experiments, and Dr Pankaj Kapahi, Jihad Skaf and Gregory Kronmal for reviewing the article. This work was supported by an RO1 from the National Institutes of Health (CA115484).
